Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLU-5937 in Refractory Chronic Cough (CALM-2) - China Extension
NCT07650084Phase 3Recruiting
- Sponsor
- GSK
- Start
- Nov 2025
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
A Phase 3 trial of camlipixant in refractory chronic cough (RCC), sponsored by GSK. Started Nov 2025; status: recruiting.
02
Drugs
camlipixant
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on NCT07650084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07650084.